NASDAQ:BDSI - BioDelivery Sciences International Stock Price, Forecast & News

BioDelivery Sciences International's stock was trading at $3.96 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, BDSI shares have decreased by 10.9% and is now trading at $3.53. View which stocks have been mosted impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioDelivery Sciences International in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for BioDelivery Sciences International.

BioDelivery Sciences International is scheduled to release its next quarterly earnings announcement on Monday, May 4th 2020. View our earnings forecast for BioDelivery Sciences International.

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) issued its quarterly earnings data on Thursday, March, 12th. The specialty pharmaceutical company reported $0.04 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.01 by $0.03. The specialty pharmaceutical company earned $31.60 million during the quarter, compared to analyst estimates of $30.10 million. BioDelivery Sciences International had a negative net margin of 13.74% and a positive return on equity of 13.41%. View BioDelivery Sciences International's earnings history.

BioDelivery Sciences International issued an update on its FY 2019 IntraDay earnings guidance on Monday, January, 13th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $110-110 million, compared to the consensus revenue estimate of $111 million.

6 brokerages have issued twelve-month price objectives for BioDelivery Sciences International's shares. Their forecasts range from $8.00 to $9.00. On average, they expect BioDelivery Sciences International's share price to reach $8.50 in the next year. This suggests a possible upside of 140.8% from the stock's current price. View analysts' price targets for BioDelivery Sciences International.

Press coverage about BDSI stock has been trending positive this week, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. BioDelivery Sciences International earned a coverage optimism score of 2.4 on InfoTrie's scale. They also assigned media headlines about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news aboutBioDelivery Sciences International.

BioDelivery Sciences International saw a increase in short interest in February. As of February 28th, there was short interest totaling 3,300,000 shares, an increase of 9.3% from the February 13th total of 3,020,000 shares. Based on an average trading volume of 1,220,000 shares, the days-to-cover ratio is presently 2.7 days. Approximately 4.0% of the shares of the company are sold short. View BioDelivery Sciences International's Current Options Chain.

Some companies that are related to BioDelivery Sciences International include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), AbbVie (ABBV), Allergan (AGN), Zoetis (ZTS), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Horizon Therapeutics (HZNP), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX) and Corcept Therapeutics (CORT).

Based on aggregate information from My MarketBeat watchlists, some companies that other BioDelivery Sciences International investors own include TG Therapeutics (TGTX), Eldorado Gold (EGO), Synergy Pharmaceuticals (SGYP), NVIDIA (NVDA), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), Progenics Pharmaceuticals (PGNX), Horizon Therapeutics (HZNP), Exelixis (EXEL) and Novavax (NVAX).

BioDelivery Sciences International trades on the NASDAQ under the ticker symbol "BDSI."

BioDelivery Sciences International's stock is owned by many different retail and institutional investors. Top institutional shareholders include Emerald Mutual Fund Advisers Trust (2.23%), State Street Corp (2.09%), Nuveen Asset Management LLC (1.99%), Geode Capital Management LLC (1.26%), Renaissance Technologies LLC (1.24%) and Goldman Sachs Group Inc. (1.05%). Company insiders that own BioDelivery Sciences International stock include Francis E Odonnell Jr, Healthcare Master Fun Broadfin, Herm Cukier, James Vollins, Mark A Sirgo, Mary Theresa Coelho, Paolantonio Ernest Robert De, Scott M Plesha and Thomas B Smith. View institutional ownership trends for BioDelivery Sciences International.

BDSI stock was sold by a variety of institutional investors in the last quarter, including Penn Capital Management Co. Inc., J. Goldman & Co LP, Mackay Shields LLC, Los Angeles Capital Management & Equity Research Inc., Oxford Asset Management LLP, PNC Financial Services Group Inc., New York State Common Retirement Fund, and California Public Employees Retirement System. Company insiders that have sold BioDelivery Sciences International company stock in the last year include Francis E Odonnell Jr, Healthcare Master Fun Broadfin, Herm Cukier, James Vollins, Mark A Sirgo, Mary Theresa Coelho, Scott M Plesha, and Thomas B Smith. View insider buying and selling activity for BioDelivery Sciences International.

BDSI stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Marshall Wace LLP, EAM Investors LLC, Nuveen Asset Management LLC, Goldman Sachs Group Inc., Panagora Asset Management Inc., Assenagon Asset Management S.A., and State Street Corp. View insider buying and selling activity for BioDelivery Sciences International.

Shares of BDSI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of BDSI stock can currently be purchased for approximately $3.53.

BioDelivery Sciences International has a market capitalization of $340.15 million and generates $111.39 million in revenue each year. The specialty pharmaceutical company earns $-15,310,000.00 in net income (profit) each year or $0.10 on an earnings per share basis. BioDelivery Sciences International employs 164 workers across the globe. View additional information about BioDelivery Sciences International.

The official website for BioDelivery Sciences International is http://www.bdsi.com/.

BioDelivery Sciences International's mailing address is 4131 PARKLAKE AVENUE SUITE 225, RALEIGH NC, 27612. The specialty pharmaceutical company can be reached via phone at 919-582-9050 or via email at [email protected]